References:
  1. De Saint Aubain Somerhausen N, Fletcher CDM. Leiomyosarcoma of soft tissue in children: Clinicopathologic analysis of 20 cases. Am J Surg Pathol. 1999;23(7):755-763. doi:10.1097/00000478-199907000-00002
  2. Steppan D, Pratilas C, Loeb D. Targeted therapy for soft tissue sarcomas in adolescents and young adults. Adolesc Health Med Ther. 2017;Volume 8:41-55. doi:10.2147/ahmt.s70377
  3. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD, 1999.4.
  4. Loeb DM, Thornton K, Shokek O. Pediatric Soft Tissue Sarcomas. Surg Clin North Am. 2008;88(3):615-627. doi:10.1016/j.suc.2008.03.008
  5. Spunt SL, Million L, Chi YY, et al. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children’s Oncology Group prospective study. Lancet Oncol. 2020;21(1):145-161. doi:10.1016/S1470-2045(19)30672-2
  6. Brennan MF. The enigma of local recurrence. Ann Surg Oncol. 1997;4(1):1-12. doi:10.1007/BF02316804
  7. Spunt SL, Hill DA, Motosue AM, et al. Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Clin Oncol. 2002;20(15):3225-3235. doi:10.1200/JCO.2002.06.066
  8. Costa R, Carneiro BA, Taxter T, et al. FGFR3-TACC3 fusion in solid tumors: Mini review. Oncotarget. 2016;7(34):55924-55938. doi:10.18632/oncotarget.10482
  9. Lasorella A, Sanson M, Iavarone A. FGFR-TACC gene fusions in human glioma. Neuro Oncol. 2017;19(4):475-483. doi:10.1093/neuonc/now240
  10. Dupain C, Harttrampf AC, Urbinati G, Geoerger B, Massaad-Massade L. Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine. Mol Ther - Nucleic Acids. 2017;6:315-326. doi:10.1016/j.omtn.2017.01.005
  11. Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (80- ). 2012;337(6099):1231-1235. doi:10.1126/science.1220834
  12. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5. doi:10.1038/ncomms5846
  13. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC Study 62043). J Clin Oncol. 2009;27(19):3126-3132. doi:10.1200/JCO.2008.21.3223